Hemophilia Disease Forecast and Market Analysis to 2035

  • ID: 3797432
  • Report
  • 473 pages
  • Datamonitor Healthcare
1 of 3
Disease Overview:

Hemophilia is a relatively rare hereditary genetic disorder characterized by an inability to produce a clot capable of stopping bleeding. Mainly men are affected by hemophilia A (factor VIII-deficient) and hemophilia B (factor IX-deficient), as is the case with most recessive, X-chromosomal disorders. In congenital hemophilia, the impaired production or functioning of one of the factors involved in the coagulation cascade is responsible for compromised blood coagulation, leading to uncontrolled and prolonged bleeding. The current standard of treatment for these patients is the replacement of the missing factor via clotting factor concentrate products. However, some patients develop antibodies against these therapies, called inhibitors, making treatment much more difficult.

Patients without hemophilia who develop inhibitors against clotting factor VIII or factor IX are diagnosed as having acquired hemophilia A or B, respectively. Although acquired hemophilia patients and congenital hemophilia patients with inhibitors share some similar traits and treatment options, acquired hemophilia affects men and women similarly, and has a distinct bleeding pattern.

Another disease associated with blood coagulation dysfunction is von Willebrand disease, which is caused by a deficiency in von Willebrand factor. Although von Willebrand disease is more common than hemophilia, it is relatively less severe, with most patients exhibiting mild disease that does not require regular treatment unless bleeding episodes caused by trauma or invasive procedures are uncontrollable.
Note: Product cover images may vary from those shown
2 of 3
1. FORECAST: HEMOPHILIA
Executive Summary
Market Overview and Trends
Methodology and Market Definition
Advate
Adynovate
Alprolix
BAX 817
BAY 94-9027
BeneFIX
CSL627
Eloctate
FEIBA
Idelvion
Ixinity
Kogenate/Helixate and Kovaltry
N8-GP
N9-GP
NovoEight
NovoSeven
Nuwiq
Rixubis
Vonvendi
Xyntha/ReFacto
Primary Research Methodology

2. TREATMENT: HEMOPHILIA
Executive Summary
Primary Research Methodology
Disease Definition and Diagnosis
Patient Segmentation
Current Treatment Options
Prescribing Trends

3. EPIDEMIOLOGY: HEMOPHILIA
Executive Summary
Disease Background
Sources and Methodology
Forecast: Hemophilia
Forecast: Von Willebrand Disease
Epidemiologist Insight
Strengths and Limitations
Appendix

4. MARKETED DRUGS: HEMOPHILIA
Executive Summary
Product Overview
Products Approved for Acquired Hemophilia
Products Approved for Von Willebrand Disease
Appendix
Product profile: Advate
Product profile: Adynovate
Product profile: Alprolix
Product profile: BeneFIX
Product profile: Eloctate
Product profile: FEIBA
Product profile: Idelvion
Product profile: Ixinity
Product profile: Kogenate FS
Product profile: NovoEight
Product profile: NovoSeven
Product profile: Rixubis
Product profile: Xyntha

5. PIPELINE: HEMOPHILIA
Executive Summary
Clinical Pipeline Overview
Target Product Profile
Clinical Trial Design
Product profile (late stage): BAX 817
Product profile (late stage): BAY 94-9027
Product profile (late stage): CSL627
Product profile (late stage): CSL689
Product profile (late stage): Kovaltry
Product profile (late stage): LR769
Product profile (late stage): N8-GP
Product profile (late stage): N9-GP
Product profile (late stage): emicizumab

6. APPENDIX
Appendix: Pipeline: Hemophilia

List of Figures:
Figure 1: Hemophilia sales across the US, Japan, and five major EU markets, by country ($m), 2014-23
Figure 2: Hemophilia sales in the US, by type of therapy ($m), 2014-23
Figure 3: Hemophilia sales in Japan, by type of therapy ($m), 2014-23
Figure 4: Hemophilia sales in the five major EU markets, by type of therapy ($m), 2014-23
Figure 5: Sales of therapies for hemophilia A across the US, Japan, and five major EU markets, by therapy type ($m), 2014-23
Figure 6: Sales of therapies for hemophilia B across the US, Japan, and five major EU markets, by therapy type ($m), 2014-23
Figure 7: Sales of long-acting therapies for hemophilia A and hemophilia B across the US, Japan, and five major EU markets ($m), 2014-23
Figure 8: Hemophilia therapy sales from prophylactic and on-demand treatment, versus on-demand treatment only ($m), 2014-23
Figure 9: Sales of therapies for von Willebrand disease across the US, Japan, and five major EU markets, by therapy type ($m), 2014-23
Figure 10: Methodology flow
Figure 11: Advate sales for hemophilia across the US, Japan, and five major EU markets, by country ($m), 2014-23
Figure 12: Adynovate sales for hemophilia across the US, Japan, and five major EU markets, by country ($m), 2014-23
Figure 13: Alprolix sales for hemophilia across the US, Japan, and five major EU markets, by country ($m), 2014-23
Figure 14: BAX 817 sales for hemophilia across the US, Japan, and five major EU markets, by country ($m), 2014-23
Figure 15: BAY 94-9027 sales for hemophilia across the US, Japan, and five major EU markets, by country ($m), 2014-23
Figure 16: BeneFIX sales for hemophilia across the US, Japan, and five major EU markets, by country ($m), 2014-23
Figure 17: CSL627 sales for hemophilia across the US, Japan, and five major EU markets, by country ($m), 2014-23
Figure 18: Eloctate sales for hemophilia across the US, Japan, and five major EU markets, by country ($m), 2014-23
Figure 19: FEIBA sales for hemophilia across the US, Japan, and five major EU markets, by country ($m), 2014-23
Figure 20: Idelvion sales for hemophilia across the US, Japan, and five major EU markets, by country ($m), 2014-23
Figure 21: Ixinity sales for hemophilia across the US, Japan, and five major EU markets, by country ($m), 2014-23
Figure 22: Combined sales for Kogenate and Kovaltry for hemophilia across the US, Japan, and five major EU markets, by country ($m), 2014-23
Figure 23: N8-GP sales for hemophilia across the US, Japan, and five major EU markets, by country ($m), 2014-23
Figure 24: N9-GP sales for hemophilia across the US, Japan, and five major EU markets, by country ($m), 2014-23
Figure 25: NovoEight sales for hemophilia across the US, Japan, and five major EU markets, by country ($m), 2014-23
Figure 26: NovoSeven sales for hemophilia across the US, Japan, and five major EU markets, by country ($m), 2014-23
Figure 27: Nuwiq sales for hemophilia across the US, Japan, and five major EU markets, by country ($m), 2014-23
Figure 28: Rixubis sales for hemophilia across the US, Japan, and five major EU markets, by country ($m), 2014-23
Figure 29: Vonvendi sales for von Willebrand disease across the US, Japan, and five major EU markets, by country ($m), 2014-23
Figure 30: Xyntha sales for hemophilia across the US, Japan, and five major EU markets, by country ($m), 2014-23
Figure 31: The intrinsic, extrinsic, and final common pathways of the clotting factor cascade
Figure 32: Percentage of hemophilia A and B patients with inhibitors across the US, Japan, and five major EU markets (%)
Figure 33: Patient segmentation by treatment strategy for hemophilia A, B, and VWD patients in the US, Japan, and five major EU markets (%)
Figure 34: Uptake of prophylactic therapy strategies among hemophilia patients in the US, Japan, and five major EU markets (%)
Figure 35: Distribution of actively treated hemophilia patients by age across the US, Japan, and five major EU markets (%)
Figure 36: Uptake of prophylactic therapy versus on-demand therapy in VWD patients in the US, Japan, and five major EU markets (%)
Figure 37: Risk factors for inhibitor formation
Figure 38: Uptake and success of immune tolerance induction therapy in hemophilia A patients across the US, Japan, and five major EU markets (%)
Figure 39: Uptake and success of immune tolerance induction therapy in hemophilia B patients across the US, Japan, and five major EU markets (%)
Figure 40: Top three brands prescribed for the prophylactic treatment of hemophilia A without inhibitors across the US, Japan, and five major EU markets (%)
Figure 41: Top three brands prescribed for the on-demand treatment of hemophilia A without inhibitors across the US, Japan, and five major EU markets (%)
Figure 42: Top three brands prescribed for the prophylactic treatment of hemophilia B without inhibitors across the US, Japan, and five major EU markets (%)
Figure 43: Top three brands prescribed for the on-demand treatment of hemophilia B without inhibitors across the US, Japan, and five major EU markets (%)
Figure 44: Top three brands prescribed for the prophylactic treatment of hemophilia A with inhibitors across the US, Japan, and five major EU markets (%)
Figure 45: Top three brands prescribed for the on-demand treatment of hemophilia A with inhibitors across the US, Japan, and five major EU markets (%)
Figure 46: Top three brands prescribed for the prophylactic treatment of hemophilia B with inhibitors across the US, Japan, and five major EU markets (%)
Figure 47: Top three brands prescribed for the on-demand treatment of hemophilia B with inhibitors across the US, Japan, and five major EU markets (%)
Figure 48: Top three brands prescribed for the prophylactic treatment of VWD across the US, Japan, and five major EU markets (%)
Figure 49: Top three brands prescribed for the on-demand treatment of VWD across the US, Japan, and five major EU markets (%)
Figure 50: Trend in diagnosed prevalent cases of hemophilia A in the US, Japan, and five major EU markets, by country, 2015-35
Figure 51: Change in diagnosed prevalent cases of hemophilia A in the US, Japan, and five major EU markets, by country, 2015-35
Figure 52: Trend in diagnosed prevalent cases of hemophilia B in the US, Japan, and five major EU markets, by country, 2015-35
Figure 53: Change in diagnosed prevalent cases of hemophilia B in the US, Japan, and five major EU markets, by country, 2015-35
Figure 54: Diagnosed prevalent cases of von Willebrand disease in the US, Japan, and five major EU markets, by country, 2015-35
Figure 55: Change in diagnosed prevalent cases of von Willebrand disease in the US, Japan and five major EU markets, by country, 2015-35
Figure 56: Advate for hemophilia A - SWOT analysis
Figure 57: Datamonitor Healthcare’s drug assessment summary of Advate in hemophilia A
Figure 58: Datamonitor Healthcare’s drug assessment summary of Advate in hemophilia A
Figure 59: Adynovate for hemophilia A - SWOT analysis
Figure 60: Datamonitor Healthcare’s drug assessment summary of Adynovate in hemophilia A
Figure 61: Datamonitor Healthcare’s drug assessment summary of Adynovate in hemophilia A
Figure 62: Alprolix for hemophilia B - SWOT analysis
Figure 63: Datamonitor Healthcare’s drug assessment summary of Alprolix in hemophilia B
Figure 64: Datamonitor Healthcare’s drug assessment summary of Alprolix in hemophilia B
Figure 65: BeneFIX for hemophilia B - SWOT analysis
Figure 66: Datamonitor Healthcare’s drug assessment summary of BeneFIX in hemophilia B
Figure 67: Datamonitor Healthcare’s drug assessment summary of BeneFIX in hemophilia B
Figure 68: Eloctate for hemophilia A - SWOT analysis
Figure 69: Datamonitor Healthcare’s drug assessment summary of Eloctate in hemophilia A
Figure 70: Datamonitor Healthcare’s drug assessment summary of Eloctate in hemophilia A
Figure 71: FEIBA for hemophilia with inhibitors - SWOT analysis
Figure 72: Datamonitor Healthcare’s drug assessment summary of FEIBA in hemophilia with inhibitors
Figure 73: Datamonitor Healthcare’s drug assessment summary of FEIBA in hemophilia with inhibitors
Figure 74: Idelvion for hemophilia B - SWOT analysis
Figure 75: Datamonitor Healthcare’s drug assessment summary of Idelvion in hemophilia B
Figure 76: Datamonitor Healthcare’s drug assessment summary of Idelvion in hemophilia B
Figure 77: Ixinity for hemophilia B - SWOT analysis
Figure 78: Datamonitor Healthcare’s drug assessment summary of Ixinity in hemophilia B
Figure 79: Datamonitor Healthcare’s drug assessment summary of Ixinity in hemophilia B
Figure 80: Kogenate FS for hemophilia A - SWOT analysis
Figure 81: Datamonitor Healthcare’s drug assessment summary of Kogenate in hemophilia A
Figure 82: Datamonitor Healthcare’s drug assessment summary of Kogenate in hemophilia A
Figure 83: NovoEight for hemophilia A - SWOT analysis
Figure 84: Datamonitor Healthcare’s drug assessment summary of NovoEight in hemophilia A
Figure 85: Datamonitor Healthcare’s drug assessment summary of NovoEight in hemophilia A
Figure 86: NovoSeven for hemophilia with inhibitors - SWOT analysis
Figure 87: Datamonitor Healthcare’s drug assessment summary of NovoSeven in hemophilia with inhibitors
Figure 88: Datamonitor Healthcare’s drug assessment summary of NovoSeven in hemophilia with inhibitors
Figure 89: Rixubis for hemophilia B - SWOT analysis
Figure 90: Datamonitor Healthcare’s drug assessment summary of Rixubis in hemophilia B
Figure 91: Datamonitor Healthcare’s drug assessment summary of Rixubis in hemophilia B
Figure 92: Xyntha for hemophilia A - SWOT analysis
Figure 93: Datamonitor Healthcare’s drug assessment summary of Xyntha in hemophilia A
Figure 94: Datamonitor Healthcare’s drug assessment summary of Xyntha in hemophilia A
Figure 95: BAX 817 for hemophilia with inhibitors - SWOT analysis
Figure 96: Datamonitor Healthcare’s drug assessment summary of BAX 817 in hemophilia with inhibitors
Figure 97: Datamonitor Healthcare’s drug assessment summary of BAX 817 in hemophilia with inhibitors
Figure 98: BAY 94-9027 for hemophilia A - SWOT analysis
Figure 99: Datamonitor Healthcare’s drug assessment summary of BAY 94-9027 in hemophilia A
Figure 100: Datamonitor Healthcare’s drug assessment summary of BAY 94-9027 in hemophilia A
Figure 101: CSL627 for hemophilia A - SWOT analysis
Figure 102: Datamonitor Healthcare’s drug assessment summary of CSL627 in hemophilia A
Figure 103: Datamonitor Healthcare’s drug assessment summary of CSL627 in hemophilia A
Figure 104: CSL689 for hemophilia with inhibitors - SWOT analysis
Figure 105: Datamonitor Healthcare’s drug assessment summary of CSL689 in hemophilia with inhibitors
Figure 106: Datamonitor Healthcare’s drug assessment summary of CSL689 in hemophilia with inhibitors
Figure 107: Kovaltry for hemophilia A - SWOT analysis
Figure 108: Datamonitor Healthcare’s drug assessment summary of Kovaltry in hemophilia A
Figure 109: Datamonitor Healthcare’s drug assessment summary of Kovaltry in hemophilia A
Figure 110: LR769 for hemophilia with inhibitors - SWOT analysis
Figure 111: Datamonitor Healthcare’s drug assessment summary of LR769 in hemophilia with inhibitors
Figure 112: Datamonitor Healthcare’s drug assessment summary of LR769 in hemophilia with inhibitors
Figure 113: N8-GP for hemophilia A - SWOT analysis
Figure 114: Datamonitor Healthcare’s drug assessment summary of N8-GP in hemophilia A
Figure 115: Datamonitor Healthcare’s drug assessment summary of N8-GP in hemophilia A
Figure 116: N9-GP for hemophilia B - SWOT analysis
Figure 117: Datamonitor Healthcare’s drug assessment summary of N9-GP in hemophilia B
Figure 118: Datamonitor Healthcare’s drug assessment summary of N9-GP in hemophilia B
Figure 119: Emicizumab for hemophilia A - SWOT analysis
Figure 120: Datamonitor Healthcare’s drug assessment summary of emicizumab in hemophilia A
Figure 121: Datamonitor Healthcare’s drug assessment summary of emicizumab in hemophilia A

List of Tables:
Table 1: Hemophilia sales across the US, Japan, and five major EU markets, by country ($m), 2014-23
Table 2: Hemophilia sales in the US, by type of therapy ($m), 2014-23
Table 3: Hemophilia sales in Japan, by type of therapy ($m), 2014-23
Table 4: Hemophilia sales in the five major EU markets, by type of therapy ($m), 2014-23
Table 5: Sales of therapies for hemophilia A across the US, Japan, and five major EU markets, by therapy type ($m), 2014-23
Table 6: Sales of therapies for hemophilia B across the US, Japan, and five major EU markets, by therapy type ($m), 2014-23
Table 7: Sales of long-acting therapies for hemophilia A and hemophilia B across the US, Japan, and five major EU markets ($m), 2014-23
Table 8: Hemophilia therapy sales from prophylactic and on-demand treatment, versus on-demand treatment only ($m), 2014-23
Table 9: Sales of therapies for von Willebrand disease across the US, Japan, and five major EU markets, by therapy type ($m), 2014-23
Table 10: Types of therapy and populations included in the hemophilia forecast
Table 11: Launch dates of key products for hemophilia across the US, Japan, and five major EU markets
Table 12: Price sources and calculations, by country
Table 13: Exchange rates used for calculating prices
Table 14: Frequency and severity of bleeding events in hemophilia
Table 15: Duration of treatment for mild, moderate, and severe bleeding events in hemophilia
Table 16: Advate sales for hemophilia across the US, Japan, and five major EU markets, by country ($m), 2014-23
Table 17: Adynovate sales for hemophilia across the US, Japan, and five major EU markets, by country ($m), 2014-23
Table 18: Alprolix sales for hemophilia across the US, Japan, and five major EU markets, by country ($m), 2014-23
Table 19: BAX 817 sales for hemophilia across the US, Japan, and five major EU markets, by country ($m), 2014-23
Table 20: BAY 94-9027 sales for hemophilia across the US, Japan, and five major EU markets, by country ($m), 2014-23
Table 21: BeneFIX sales for hemophilia across the US, Japan, and five major EU markets, by country ($m), 2014-23
Table 22: CSL627 sales for hemophilia across the US, Japan, and five major EU markets, by country ($m), 2014-23
Table 23: Eloctate sales for hemophilia across the US, Japan, and five major EU markets, by country ($m), 2014-23
Table 24: FEIBA sales for hemophilia across the US, Japan, and five major EU markets, by country ($m), 2014-23
Table 25: Idelvion sales for hemophilia across the US, Japan, and five major EU markets, by country ($m), 2014-23
Table 26: Ixinity sales for hemophilia across the US, Japan, and five major EU markets, by country ($m), 2014-23
Table 27: Combined sales for Kogenate and Kovaltry for hemophilia across the US, Japan, and five major EU markets, by country ($m), 2014-23
Table 28: N8-GP sales for hemophilia across the US, Japan, and five major EU markets, by country ($m), 2014-23
Table 29: N9-GP sales for hemophilia across the US, Japan, and five major EU markets, by country ($m), 2014-23
Table 30: NovoEight sales for hemophilia across the US, Japan, and five major EU markets, by country ($m), 2014-23
Table 31: NovoSeven sales for hemophilia across the US, Japan, and five major EU markets, by country ($m), 2014-23
Table 32: Nuwiq sales for hemophilia across the US, Japan, and five major EU markets, by country ($m), 2014-23
Table 33: Rixubis sales for hemophilia across the US, Japan, and five major EU markets, by country ($m), 2014-23
Table 34: Vonvendi sales for von Willebrand disease across the US, Japan, and five major EU markets, by country ($m), 2014-23
Table 35: Xyntha sales for hemophilia across the US, Japan, and five major EU markets, by country ($m), 2014-23
Table 36: Hematologists surveyed for the hemophilia primary research study, 2013
Table 37: Hematologists, hematology internal medicine specialists, and pediatric hematologists surveyed for the hemophilia primary research study, 2016
Table 38: Sites and severity of bleeding in hemophilia A and B
Table 39: Most common bleeding symptoms of healthy individuals versus patients diagnosed with VWD
Table 40: Severity of hemophilia and related bleeding episodes
Table 41: Clinical and etiological features of von Willebrand types
Table 42: Historical overview and evaluation of the development of hemophilia therapies
Table 43: Commonly used guidelines for the treatment of hemophilia and VWD
Table 44: Patient segmentation by treatment strategy for hemophilia A patients without inhibitors in the US, Japan, and five major EU markets
Table 45: Patient segmentation by treatment strategy for hemophilia A patients with inhibitors in the US, Japan, and five major EU markets
Table 46: Patient segmentation by treatment strategy for hemophilia B patients without inhibitors in the US, Japan, and five major EU markets
Table 47: Patient segmentation by treatment strategy for hemophilia B patients with inhibitors in the US, Japan, and five major EU markets
Table 48: Patient segmentation by treatment strategy for VWD in the US, Japan, and five major EU markets
Table 49: Types of von Willebrand disease
Table 50: Severity of hemophilia and related bleeding episodes
Table 51: Diagnosed prevalent cases of hemophilia A in the US, Japan, and five major EU markets, by country, 2015-35
Table 52: Age-specific diagnosed prevalent cases of hemophilia A in the US, Japan, and five major EU markets, by country, 2015
Table 53: Diagnosed prevalent cases of hemophilia A in the US, Japan, and five major EU markets, by severity and country, 2015
Table 54: Diagnosed prevalent cases of hemophilia A in the US, Japan, and five major EU markets, by presence of inhibitors and country, 2015
Table 55: Diagnosed prevalent cases of hemophilia A in the US, Japan, and five major EU markets, by presence of co-morbid infectious disease and country, 2015
Table 56: Diagnosed prevalent cases of hemophilia B in the US, Japan, and five major EU markets, by country, 2015-35
Table 57: Age-specific diagnosed prevalent cases of hemophilia B in the US, Japan, and five major EU markets, by country, 2015
Table 58: Diagnosed prevalent cases of hemophilia B in the US, Japan, and five major EU markets, by severity and country, 2015
Table 59: Diagnosed prevalent cases of hemophilia B in the US, Japan, and five major EU markets, by presence of inhibitors and country, 2015
Table 60: Diagnosed prevalent cases of hemophilia B in the US, Japan, and five major EU markets, by presence of co-morbid infectious disease and country, 2015
Table 61: Diagnosed prevalent cases of von Willebrand disease in the US, Japan, and five major EU markets, by country, 2015-35
Table 62: Age-specific diagnosed prevalent cases of von Willebrand disease in the US, Japan, and five major EU markets, by country, 2015
Table 63: Gender-specific diagnosed prevalent cases of von Willebrand disease in the US, Japan, and five major EU markets, by country, 2015
Table 64: Diagnosed prevalent cases of von Willebrand disease in the US, Japan, and five major EU markets, by type and country, 2015
Table 65: Key marketed drugs for hemophilia
Table 66: Obizur drug profile
Table 67: NovoSeven drug profile
Table 68: Alphanate drug profile
Table 69: Humate P drug profile
Table 70: Wilate drug profile
Table 71: Vonvendi drug profile
Table 72: Advate drug profile
Table 73: Advate pivotal trial data in hemophilia A
Table 74: Advate ongoing late-phase clinical trials in hemophilia A
Table 75: Adynovate drug profile
Table 76: Adynovate pivotal trial data in hemophilia A
Table 77: Adynovate ongoing late-phase clinical trials in hemophilia A
Table 78: Alprolix drug profile
Table 79: Alprolix pivotal trial data in hemophilia B
Table 80: Alprolix ongoing late-phase clinical trials in hemophilia B
Table 81: BeneFIX drug profile
Table 82: BeneFIX pivotal trial data in hemophilia B
Table 83: BeneFIX late-phase trial data in hemophilia B
Table 84: Eloctate drug profile
Table 85: Eloctate pivotal trial data in hemophilia A
Table 86: Eloctate ongoing late-phase clinical trials in hemophilia A
Table 87: FEIBA drug profile
Table 88: FEIBA pivotal trial data in hemophilia with inhibitors
Table 89: Idelvion drug profile
Table 90: Idelvion pivotal trial data in hemophilia B
Table 91: Idelvion ongoing late-phase clinical trials in hemophilia B
Table 92: Ixinity drug profile
Table 93: Ixinity pivotal trial data in hemophilia B
Table 94: Ixinity ongoing late-phase clinical trials in hemophilia B
Table 95: Kogenate FS drug profile
Table 96: Kogenate FS pivotal trial data in hemophilia A
Table 97: NovoEight drug profile
Table 98: NovoEight pivotal trial data in hemophilia A
Table 99: NovoEight ongoing late-phase clinical trials in hemophilia A
Table 100: NovoSeven drug profile
Table 101: NovoSeven pivotal trial data in hemophilia with inhibitors
Table 102: Rixubis drug profile
Table 103: Rixubis pivotal trial data in hemophilia B
Table 104: Rixubis late-phase trial data in hemophilia B
Table 105: Rixubis ongoing late-phase clinical trials in hemophilia B
Table 106: Xyntha drug profile
Table 107: Xyntha pivotal trial data in hemophilia A
Table 108: Xyntha ongoing late-phase clinical trials in hemophilia A
Table 109: Phase III pipeline products in development for hemophilia
Table 110: Gene therapies in early-phase development for hemophilia
Table 111: Eloctate drug profile
Table 112: Eloctate pivotal trial data in hemophilia A
Table 113: Alprolix drug profile
Table 114: Alprolix pivotal trial data in hemophilia B
Table 115: NovoSeven drug profile
Table 116: NovoSeven pivotal trial data in hemophilia with inhibitors
Table 117: BAX 817 drug profile
Table 118: BAX 817 Phase III data in hemophilia with inhibitors
Table 119: BAY 94-9027 drug profile
Table 120: BAY 94-9027 Phase III trials in hemophilia A
Table 121: CSL627 drug profile
Table 122: CSL627 Phase III data in hemophilia A
Table 123: CSL627 Phase III trials in hemophilia A
Table 124: CSL689 drug profile
Table 125: CSL689 Phase III trials in hemophilia with inhibitors
Table 126: Kovaltry drug profile
Table 127: Kovaltry Phase III data in hemophilia A
Table 128: LR769 drug profile
Table 129: LR769 Phase III trials in hemophilia with inhibitors
Table 130: N8-GP drug profile
Table 131: N8-GP Phase III data in hemophilia A
Table 132: N8-GP Phase III trials in hemophilia A
Table 133: N9-GP drug profile
Table 134: N9-GP Phase III data in hemophilia B
Table 135: N9-GP Phase III trials in hemophilia B
Table 136: Emicizumab drug profile
Table 137: Emicizumab Phase III trials in hemophilia A
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll